Juliana C Cunico Dallagnol

Juliana C Cunico Dallagnol

Auto-generated profile, based on publicly available information

Juliana C Cunico Dallagnol

Institut National de la Recherche Scientifique, Centre Armand-Frappier Santé Biotechnologie, Groupe de Recherche en Ingénierie des Peptides et en Pharmacothérapie (GRIPP), Université du Québec, Laval, Québec H7V 5B7, Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
XWXiaozheng Wei
Xiaozheng Wei
SDSitan Diarra
Sitan Diarra
ADAntoine Douchez
Antoine Douchez
JDJuliana C Cunico Dallagnol
Juliana C Cunico Dallagnol
THTerry Hebert
Terry Hebert
William D. LubellWilliam D. Lubell
William D. Lubell

5 August 2021 in Journal of Thermal Analysis and Calorimetry
Verified
Journal Article
Closed access
PDF file
Jaqueline CarneiroJaqueline Carneiro
Jaqueline Carneiro
JDJuliana C. C. Dallagnol
Juliana C. C. Dallagnol
AVAndressa Veiga
Andressa Veiga
MNMiguel Daniel Noseda
Miguel Daniel Noseda
MDMaria Eugênia Rabello Duarte
Maria Eugênia Rabello Duarte
Fábio Seigi MurakamiFábio Seigi Murakami
Fábio Seigi Murakami

22 October 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
ALAnnik Lanoie
Annik Lanoie
SFSára Ferková
Sára Ferková
ÉCÉdouard Caron-Duval
Édouard Caron-Duval
JDJuliana C.C. Dallagnol
Juliana C.C. Dallagnol
SDSitan Diarra
Sitan Diarra
PSPhilippe Sarret
Philippe Sarret
Contulakins are a subclass of conopeptides derived from cone snail venom, known for their analgesic properties mediated through activation of neurotensin receptors NTS1 and NTS2. Among them, contulakin-G, isolated from Conus geographus, exhibits a favorable pharmacokinetic profile, including a 24-hour plasma half-life, and produces potent opioid-independent antinociceptive effects. To facilitate synthesis while preserving analgesic efficacy, we investigated the structure-activity relationships of contulakin-G, focusing on modifications to the glycosylated Thr10 residue. In the first series, Thr10 was substituted by natural and non-natural amino acids encompassing diverse physiochemical and steric properties. Most substitutions had minimal impact on receptor affinity, though some increased the NTS2/NTS1 selectivity ratio. Of these, only the Tyr10 analog retained antinociceptive efficacy comparable to native contulakin-G. Building on tyrosine's hydrophobicity, a second series introduced non-natural hydrophobic residues at position 10, including Gln-cycloheptyl, Gln-biphenylmethyl, and Gln-dimethyladamantyl, along with a non-glycosylated form. In both tonic and postoperative pain models, the non-glycosylated and Gln-cycloheptyl analogs demonstrated potent analgesic activity, comparable to contulakin-G and reversed mechanical allodynia in a neuropathic pain model. In contrast, a third series involving N-terminal truncations led to reduced plasma half-life and loss of antinociceptive efficacy, underscoring the importance of the N-terminal region. Molecular modeling further revealed that full-length analogs engage a broader NTS2 binding interface than truncated derivatives. These findings support the development of synthetically accessible contulakin-G analogs as promising non-opioid analgesics.

23 August 2023 in ACS Chemical Biology
Verified
Journal Article
Closed access
JDJuliana C. C. Dallagnol
Juliana C. C. Dallagnol
MVMikhail Volkovich
Mikhail Volkovich
DCDavid Chatenet
David Chatenet
BABruce G. Allen
Bruce G. Allen
THTerry Hebert
Terry Hebert

10 October 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
JDJulia de Paula Dutra
Julia de Paula Dutra
JDJuliana C.C. Dallagnol
Juliana C.C. Dallagnol
THTuan Anh Hoang
Tuan Anh Hoang
HNHassan Nassour
Hassan Nassour
THTerry Hebert
Terry Hebert
David ChatenetDavid Chatenet
David Chatenet
Evidence across G protein-coupled receptor systems indicates that subtle modifications in three-dimensional ligand architecture can profoundly influence receptor signaling. However, the contribution of conformational constraints at the Trp4 position, of the urotensin II-related peptide (URP), to signal transduction and functional selectivity at the human urotensin II receptor (hUTR) remains poorly understood. Here, we revisited a series of previously described conformationally constrained URP analogs and comprehensively characterized their signaling profiles at the hUTR. Signaling outputs of [D-Tiq4]URP, [L-Tpi4]URP, [D-Aia4]URP, and [D-Phg4]URP were evaluated using bioluminescence resonance energy transfer (BRET)-based assays to monitor Gaq, Ga12, DAG production, PKN1 activation and β-arrestin1/2 recruitment. Ligand bias was quantified using the operational model of partial agonism Log(t/KA). Despite displaying nanomolar binding affinities (ranging from 9 to 60 nM) and reaching maximal contractile responses comparable or superior to the reference URP, the analogs exhibited markedly distinct signaling signatures. [L-Tpi4]URP showed partial agonism across all pathways except Gaq, despite binding affinity comparable to URP. [D-Aia4]URP produced a more pronounced reduction in signaling outputs compared to URP, with a pronounced reduction in potency for Gaq activation. In contrast, the smaller analogs [D-Phg4]URP and [D-Tiq4]URP evoked potent Gaq activation. Notably, [D-Tiq4]URP was the only analog that preserved β-arrestin recruitment at levels comparable to URP. Collectively, these findings demonstrate that conformational restriction at Trp4 can differentially modulate hUTR signaling while preserving receptor recognition, highlighting this position as a critical structural determinant of functional selectivity and ligand-directed signaling.